1 / 24

K. Dimitriadis, PhD, FESC Consultant Cardiologist First Cardiology Clinic, University of Athens,

Meeting of the Balkan Excellent Centers “The Greek experience of Renal Denervation in resistant hypertension”. K. Dimitriadis, PhD, FESC Consultant Cardiologist First Cardiology Clinic, University of Athens, Hippokration Hospital. Abstract.

cpitt
Télécharger la présentation

K. Dimitriadis, PhD, FESC Consultant Cardiologist First Cardiology Clinic, University of Athens,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Meeting of the Balkan Excellent Centers “The Greek experience of Renal Denervation in resistant hypertension” K. Dimitriadis, PhD, FESC Consultant Cardiologist First Cardiology Clinic, University of Athens, Hippokration Hospital

  2. Abstract The first renal denervation (RDN) procedures in Greece were performed in the First Cardiology Clinic, University of Athens, Hippokration Hospital by Prof. Costas Tsioufis in patients with severe drug-resistant hypertension.1 During the last 5 years numerous patients have undergone RDN in this center which participates in international studies and registries and important experience has been gathered regarding the safety and efficacy of this interventional therapy. In an attempt to identify responders to RDN therapy in an animal setting, we have shown that RDN causes an acute and chronic alteration in renal blood flow as well as resistive index,2 whereas stimulation of the renal arteries did not lead to augmentation of blood pressure (BP) in swines in contrast to previous reports.3 The Hippokration Hospital was also one of the few centers globally for the EnligHTN I study the first-in-human study with the use of the multielectrode RDN catheter. From this population important papers regarding the effect of RDN besides BP,4 on left ventricular mass with up to 24 months follow-up have been published.5,6 In Greece, the Hellenic Cardiological Society and the Working Group Hypertension and the Heart of the Society have organized a national registry on patients with resistant hypertension under the name Herhodotos with data on more than 300 cases providing a useful insight into the characteristics of potential candidates for RDN. Additionally, the Greek RDN registry has taken place in 4 Greek hospital centers including patients with drug resistant hypertension. In this “real-world’ multicenter national registry, the efficacy of renal denervation in reducing BP as well as safety is proven during a 12 months follow-up. Moreover, younger age and higher levels of baseline office systolic BP are independently related to better BP response to RDN.

  3. RDN in Greece First Cases in Hippokration Hospital in 2011 2 cases of patients with RHT

  4. Renal Sympathetic Denervation The Greek experience in the Hippocration Hospital Clinical and pre-clinical Global Simplicity Registry EnligHTN I (FIM) EnligHTN II MS study Greek RDN registry

  5. Animal studies for indentification of reliable markers of intra-procedural success TsioufisC, et al. Int J Cardiol 2014 Tsioufis C, Papademetriou V, Dimitriadis Ket al. Int J Cardiol 2012

  6. ENLIGHTN I study

  7. Results: LV Mass Index Tsioufis C, Papademertriou V, Dimitriadis K, et al. J Hypertens. 2015

  8. LV hypertrophy status changes • After RDN, the number of patients with concentric LV hypertrophy (decreased from 16 patients (80%) at baseline to 10 patients (50%) at 12 months, and to 7 patients (36.8%) at 24 months 8CONFIDENTIAL-Do not distribute Tsioufis C, Papademetriou V, Dimitriadis K, et al. J Hum Hypertens 2016

  9. RDN in MS patiens C.Tsioufis, K.Dimitriadis,A.Kasiakogias, et al. ESH 2016

  10. The first Greek registry of patients with Resistant Hypertension Endorsed by the Hellenic Cardiac Society and the WG of Hypertension and the Heart

  11. HERHODOTOS REGISTRY Excellence centers Till today >300 pts registered

  12. HERHODOTOS REGISTRY

  13. HERHODOTOS REGISTRY

  14. Greek RDN registry 4 centers in Greece Athens-Hippokration Hospital C. Tsioufis Heraklion Crete M. Marketou Patras P. Davlouros Τhessaloniki A. Ziakas

  15. Greek RDN registry: Baseline characteristics

  16. Greek RDN registry: Baseline BP

  17. Greek RDN registry: Baseline therapy

  18. Office and ambulatory SBP after RDN at 6 and 12 months -30 mmHg -29 mmHg -13 mmHg -12mmHg

  19. Office and ambulatory DBP after RDN at 6 and 12 months -9mmHg -11mmHg -12mmHg -10mmHg

  20. BP response to RDN 85% (59 pts) with an at least 10 mmHg office SBP reduction Patients that were RDN responders (85%, n=58), compared to non-responders were younger (57±9 vs 65±8 years, p<0.05), had higher baseline office systolic BP (176±17 vs 160±11 mmHg, p<0.05) and 24h systolic BP (159±13 vs 149±11 mmHg, p<0.05).

  21. Correlation of office BP reduction at 12 months with baseline office BP r=0.402, p=0.008

  22. Correlation of 24h SBP reduction at 12 months with baseline 24h SBP r=0.3673 p=0.027

  23. ESH excellence centers Collaborate Exchange experiences In order to improve delivered therapies in the field of RDN

  24. Thank you

More Related